Literature DB >> 9608511

Targeted gene misexpression in chick limb buds using avian replication-competent retroviruses.

M Logan1, C Tabin.   

Abstract

The methods and applications for using avian replication-competent retroviruses to target gene misexpression in the developing limb bud of the chicken are described. These viruses provide the means to exploit the strengths of the chick as a model system in experimental embryology in conjunction with a genetic approach for ectopically expressing a gene of interest. The applications and strengths of the system are detailed. All the steps required to produce a virus carrying a transgene of interest and the methodologies behind designing and carrying out misexpression strategies are outlined, and some useful techniques for analyzing infected embryos are described.

Entities:  

Mesh:

Year:  1998        PMID: 9608511     DOI: 10.1006/meth.1998.0595

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  43 in total

1.  Synergistic regulation of vertebrate muscle development by Dach2, Eya2, and Six1, homologs of genes required for Drosophila eye formation.

Authors:  T A Heanue; R Reshef; R J Davis; G Mardon; G Oliver; S Tomarev; A B Lassar; C J Tabin
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

Review 2.  Vascularization of the developing chick limb bud: role of the TGFbeta signalling pathway.

Authors:  Neil Vargesson
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

3.  Wdr5 is required for chick skeletal development.

Authors:  Shimei Zhu; Eric D Zhu; Sylvain Provot; Francesca Gori
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

4.  Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.

Authors:  Jennifer L Bromberg-White; Craig P Webb; Veronique S Patacsil; Cindy K Miranti; Bart O Williams; Sheri L Holmen
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Altered Twist1 and Hand2 dimerization is associated with Saethre-Chotzen syndrome and limb abnormalities.

Authors:  Beth A Firulli; Dayana Krawchuk; Victoria E Centonze; Neil Vargesson; David M Virshup; Simon J Conway; Peter Cserjesi; Ed Laufer; Anthony B Firulli
Journal:  Nat Genet       Date:  2005-02-27       Impact factor: 38.330

6.  Noncanonical frizzled signaling regulates cell polarity of growth plate chondrocytes.

Authors:  Yuwei Li; Andrew T Dudley
Journal:  Development       Date:  2009-02-18       Impact factor: 6.868

7.  Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic chondrodysplasia-type Grebe.

Authors:  Luitgard M Graul-Neumann; Alexandra Deichsel; Ulrike Wille; Naseebullah Kakar; Randi Koll; Christian Bassir; Jamil Ahmad; Valerie Cormier-Daire; Stefan Mundlos; Christian Kubisch; Guntram Borck; Eva Klopocki; Thomas D Mueller; Sandra C Doelken; Petra Seemann
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

8.  ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.

Authors:  Julia Haupt; Alexandra Deichsel; Katja Stange; Cindy Ast; Renata Bocciardi; Roberto Ravazzolo; Maja Di Rocco; Paola Ferrari; Antonio Landi; Frederick S Kaplan; Eileen M Shore; Carsten Reissner; Petra Seemann
Journal:  Hum Mol Genet       Date:  2014-05-22       Impact factor: 6.150

9.  Demonstration of the interaction of transforming growth factor beta 2 and type X collagen using a modified tandem affinity purification tag.

Authors:  Maozhou Yang; Xinli Wang; Liang Zhang; Chiyang Yu; Bingbing Zhang; William Cole; Greg Cavey; Paula Davidson; Gary Gibson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-10-15       Impact factor: 3.205

10.  The transcriptional cofactor Lbh regulates angiogenesis and endochondral bone formation during fetal bone development.

Authors:  K L Conen; S Nishimori; S Provot; H M Kronenberg
Journal:  Dev Biol       Date:  2009-07-14       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.